<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02539966</url>
  </required_header>
  <id_info>
    <org_study_id>HCT6200</org_study_id>
    <nct_id>NCT02539966</nct_id>
  </id_info>
  <brief_title>Safety &amp; Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold</brief_title>
  <acronym>FANTOM II</acronym>
  <official_title>Safety &amp; Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>REVA Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>REVA Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FANTOM II trial is intended to assess safety and performance of the Fantom Bioresorbable
      Coronary Scaffold in native coronary arteries.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE) - Cohorts A, B and C</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiac Death, Myocardial Infarction (Q-Wave, Non Q-wave: CK-MB &gt;5X ULN) (MI), and target lesion revascularization (TLR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C</measure>
    <time_frame>6 months</time_frame>
    <description>Late Lumen Loss</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative Coronary Angiography (QCA) derived parameters - Cohort B</measure>
    <time_frame>9 months</time_frame>
    <description>Late Lumen Loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C</measure>
    <time_frame>6 months</time_frame>
    <description>Minimum Lumen Diameter (MLD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Coronary Angiography (QCA) derived parameters - Cohort B</measure>
    <time_frame>9 months</time_frame>
    <description>Minimum Lumen Diameter (MLD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C</measure>
    <time_frame>6 months</time_frame>
    <description>% Diameter Stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Coronary Angiography (QCA) derived parameters - Cohort B</measure>
    <time_frame>9 months</time_frame>
    <description>% Diameter Stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C</measure>
    <time_frame>6 months</time_frame>
    <description>Binary Restenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Coronary Angiography (QCA) derived parameters - Cohort B</measure>
    <time_frame>9 months</time_frame>
    <description>Binary Restenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE) - Cohorts A, B and C</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Cardiac Death, Myocardial Infarction (Q-Wave, Non Q-wave: CK-MB &gt;5X ULN) (MI), and target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR) - Cohorts A, B and C</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Percentage of patients with TLR at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR) - Cohorts A, B and C</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Percentage of patients with TVR at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF) - Cohorts A, B and C</measure>
    <time_frame>12, 24, 36, 48 and 60 months</time_frame>
    <description>Percentage of patients with TVF at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Technical Success - Cohorts A, B and C</measure>
    <time_frame>Day 0</time_frame>
    <description>Successful acute delivery and deployment of the device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success - Cohorts A, B and C</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of patients with angiographic success (final diameter stenosis &lt;50% without occurrence of MACE)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group A (6-month angiographic follow-up)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group B (9-month angiographic follow-up)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group C (6-month angiographic follow-up), Long Lesion/Multi-Vessel</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold</intervention_name>
    <description>Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has evidence of myocardial ischemia or a positive functional study

          -  Target lesion has a visually estimated stenosis of ≥50% and &lt;100%

          -  Target lesion is located in a native coronary artery with average reference vessel
             diameter ≥ 2.5mm and ≤ 3.5mm

          -  Lesion length ≤ 20 mm by visual estimate (N/A for Cohort C)

          -  Baseline TIMI flow ≥ 2

        Exclusion Criteria:

          -  The patient has experienced an acute myocardial infarction (AMI: STEMI or NSTEMI)
             within 72 hours of the procedure and either CK-MB or Troponin has not returned to
             within 2X ULN.

          -  Patient has a left ventricular ejection fraction &lt; 40%

          -  Patient has unprotected left main coronary disease with ≥50% stenosis

          -  The target vessel is totally occluded (TIMI Flow 0 or 1)

          -  Target lesion involves a bifurcation (a lesion with a side branch ≥ 1.5 mm in diameter
             containing a ≥ 50% stenosis).

          -  Target lesion is located within a bypass graft

          -  Target lesion has possible or definite thrombus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Abizaid, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Dante Pazzanese de Cardiologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph K Naber, PD Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elisabeth-Krankenhaus Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey Anderson</last_name>
    <phone>858-966-3038</phone>
    <email>janderson@revamedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital (Eastern Heart)</name>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Hospital</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital (Skejby)</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>institut Hospitalier J.Cartier</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>La Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Am Urban Hospital, Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Friedrichshein Hospital, Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephan Kische, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St.- Johannes-Hospital Dortmund</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joachim Weber-Albers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Krankenhaus Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Norbert Frey, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krakowskie Centrum Kardiologii Inwazyjnej</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Panskiego UM w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oddział Kardiologii Inwazyjnej I Katedra</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2015</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

